Financial advantages of SME status
Financial advantages of SME status
Financial advantages of SME status
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)
Timetable: Extension application - ATMP
Human medicines European public assessment report (EPAR): Pheburane, sodium phenylbutyrate, Date of authorisation: 30/07/2013, Revision: 13, Status: Authorised
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Pharmacovigilance Working Party (PhVWP-V) 2025
Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts - As adopted by EMA Management Board on 11-12 December 2024
Policy 58: European Medicines Agency policy on the handling of competing interests of Management Board members - As adopted by EMA Management Board on 11-12 December 2024
Minutes - HMA-EMA joint Big Data Steering Group teleconference - 11 December 2024
Revised rules on handling of competing interests published
Outcome of Public consultation on Policy 0044 - Summary of comments and EMA feedback